Pricing Log in Create free account
Saturday 17 October 2026 Export IRMD’s income statement to Excel — free account

iRadimed Corporation

IRMD Healthcare Medical Devices

iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 8.89% and free cash flow grew 11.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

88.27 1.10 −1.23%
Market cap
$1.1B
P/E
48.5×
Fwd P/E
48.7×
Dividend yield
0.87%
F-score
6/9
Altman Z
55.62
Beneish M
−2.55
Dividend safety
40/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 18.86
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 6 7 4 1 5 4 4 2 — — 1 —
Insider Ownership 34.84%

Capital & Financial Ratios $m

Market Cap 1,140.00
Revenue 86.34
Net Income 23.06
Free Cash Flow 24.55
Net Debt (59.08)
Current Ratio 9.46 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 48.50 (above 35: high)
Fwd P/E 48.70 (above 35: high)
P/S ratio 13.07 (above 10: high)
P/B ratio 11.09 (above 6: high)
Past 5Y EPS Growth 73.91% (at or above 15%: strong)
This Y EPS Growth 9.50%
Next Y EPS Growth 16.09% (at or above 15%: strong)
Next Y revenue growth 9.85%
Next 5Y EPS Growth 12.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 12.4×, against a ten-year median of 7.7×; over the ten years it ranged from 2.0× in 2017 to 15.1× in 2026.
P/E against its own 10 years 66.83%
10-year low 10-year high
P/S against its own 10 years 90.34%
10-year low 10-year high
P/B against its own 10 years 93.29%
10-year low 10-year high
EV/Sales against its own 10 years 91.15%
10-year low 10-year high
EV/FCF against its own 10 years 56.14%
10-year low 10-year high

Dividends

Payout Ratio 0.43
Annual Dividend Rate 0.77
Annual Dividend Yield 0.87%
total individual payouts
2026 0.60
0.20
0.20
0.20
2025 0.68
0.17
0.17
0.17
0.17
0.50
2024 0.45
0.15
0.15
0.15
2023 0.15
1.05
0.15
2022 0.00
1.00
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 50 52 51 59
Receivables 12 11 14 13
Inventory 13 10 12 12
Other — — — —
76 75 81 87
2023 2024 2025 Q'26
Payables 2 2 2 2
ST’ Debt — — — —
Other 0 1 0 0
16 9 10 9

Compound Annual Growth %

10y 5y 3y
Sales 10.25% 21.45% 16.28%
Cash Flow 12.55% 33.80% 35.43%
Earnings 11.56% 75.02% 20.56%
Book Value 11.47% 9.04% 8.70%

Revenue $m

Mar Jun Sep Dec Year
’26 22 20 — — —
’25 20 20 21 23 84
’24 18 18 18 19 73
’23 15 16 17 17 66
’22 12 13 13 15 53
’21 9 10 11 12 42
’20 9 7 8 9 32
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 8 6 — — —
’25 4 8 7 6 25
’24 4 7 9 6 26
’23 5 4 1 4 13
’22 1 2 4 3 10
’21 1 4 3 3 11
’20 1 1 1 2 6
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 8 5 — — —
’25 0 5 6 6 17
’24 3 5 5 3 17
’23 (2) 3 1 3 5
’22 1 1 3 3 8
’21 1 3 3 3 11
’20 1 1 1 2 5
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.45 0.41 — — —
’25 0.37 0.45 0.43 0.50 1.75
’24 0.32 0.38 0.40 0.40 1.50
’23 0.27 0.33 0.40 0.36 1.35
’22 0.20 0.26 0.27 0.29 1.02
’21 0.11 0.12 0.20 0.31 0.74
’20 0.14 (0.17) 0.09 0.05 0.11
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 8.95 7.85 12.51 16.68 14.42 21.65 26.00 27.87 40.18 47.48

Analyst estimates 2026–2028

Powerpack
High 28.00 15.75 38.78 29.80 28.43 48.75 55.92 51.04 57.95 98.53
People
People Employees 80 83 95 114 110 110 123 148 160 166
Revenue/emp, $m 0.41 0.28 0.32 0.34 0.29 0.38 0.43 0.44 0.46 0.50
Income, $m
Income, $m Revenue 32 23 30 39 32 42 53 66 73 84
Gross margin, % 81.06 75.87 76.31 77.11 74.33 76.65 77.45 76.50 76.94 76.75
EBT 11 1 6 9 (1) 10 16 22 24 28
EBT margin, % 33.70 6.05 20.36 23.48 (1.94) 23.52 30.36 33.16 33.14 33.84
Net income 7 0 6 10 1 9 13 17 19 22
Depreciation 1 1 1 1 1 1 1 1 1 1
Per share, $
Per share, $ Revenue 3.00 2.17 2.83 3.41 2.62 3.39 4.24 5.20 5.78 6.59
Earnings 0.67 0.05 0.59 0.85 0.11 0.76 1.02 1.36 1.52 1.77
Cash flow 0.87 0.32 0.69 0.91 0.48 0.91 0.80 1.07 2.02 1.96
Capex (0.14) (0.08) (0.02) (0.04) (0.05) (0.06) (0.15) (0.64) (0.70) (0.66)
Free cash flow 0.73 0.24 0.66 0.86 0.43 0.85 0.65 0.43 1.33 1.30
Book value 2.95 3.10 3.90 4.92 5.06 5.85 5.86 5.67 6.85 7.44
Shares, m 11 11 11 11 12 12 13 13 13 13
Valuation, ×
Valuation, × P/E 16.47 306.00 41.46 27.19 190.00 61.61 27.92 34.77 35.95 54.96
P/S 3.73 7.05 8.65 6.85 8.72 13.64 6.71 9.09 9.51 14.77
P/B 3.80 4.94 6.27 4.75 4.50 7.90 4.86 8.34 8.03 13.08
EV/Sales 2.94 5.91 7.52 5.65 7.08 12.15 5.63 8.33 8.80 14.16
EV/FCF 13.38 53.67 32.34 22.59 45.01 49.53 42.14 121.76 40.71 76.28
Cash, $m
Cash, $m Operating cash flow 9 3 7 10 6 11 10 13 26 25
Capex (2) (1) 0 0 (1) (1) (2) (8) (9) (8)
Free cash flow 8 3 7 10 5 11 8 5 17 17
Balance, $m
Balance, $m Working capital 30 31 40 53 59 69 69 60 67 71
Total debt — — — 3 3 2 2 — — —
Net debt (26) (26) (34) (46) (52) (63) (58) (50) (52) (51)
Shareholders’ equity 32 33 42 56 61 72 74 71 87 95
Returns, %
Returns, % ROA 19.92 1.31 14.42 16.72 1.99 12.12 15.24 19.35 20.20 21.71
ROIC 109.91 12.19 49.58 58.28 (5.02) 63.44 62.16 57.82 39.69 37.60
ROE 22.61 1.54 16.84 19.76 2.34 13.96 17.59 23.70 24.31 24.78
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

iRadimed Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BVS Bioventus Inc. $1.2B 16.4× 21.4× +3.76% (above 0%: growing) +345.45% (above 0%: growing) −25.11% (below 0%: shrinking) 68.97% 12.48% Compare
TNDM Tandem Diabetes Care, Inc. $1.2B — (loss-making) — (loss-making) +5.77% (above 0%: growing) n/m −146.34% (below 0%: shrinking) 56.87% (5.42%) Compare
IRMD iRadimed Corporation $1.1B 48.5× 48.7× +0.28% (above 0%: growing) −8.89% (below 0%: shrinking) +11.66% (above 0%: growing) 74.07% 31.23%
ENOV Enovis Corporation $1.1B — (loss-making) 195× +3.23% (above 0%: growing) n/m +815.79% (above 0%: growing) 61.64% 2.99% Compare
AORT Artivion, Inc. $1.1B — (loss-making) 142× +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
CBLL CeriBell, Inc. $1.1B — (loss-making) — (loss-making) +32.54% (above 0%: growing) n/m −68.63% (below 0%: shrinking) 92.32% (71.11%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B — (loss-making) 26.1× +0.76% (above 0%: growing) n/m +193.48% (above 0%: growing) 52.47% 4.61% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.0B — (loss-making) 14.2× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
PRCT PROCEPT BioRobotics Corporation $1.0B — (loss-making) — (loss-making) +19.34% (above 0%: growing) n/m −24.43% (below 0%: shrinking) 66.01% (28.98%) Compare
Median of peers $1.1B — 26.1× +6.80% — −24.77% 62.84% (1.21%)

All 149 Medical Devices stocks →

iRadimed Corporation (IRMD) key facts

  • Strength: iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024.
  • Strength: Net income was $22.5 million, or $1.77 per share (basic), a net margin of 26.8%.
  • iRadimed Corporation (IRMD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IRMD traded at $88.27, a market capitalization of $1.1 billion.
  • At that price the stock trades at 48.5× trailing-twelve-month earnings and 13.1× sales; its P/E is higher than 67% of its own readings over the past ten years.
  • iRadimed Corporation pays an annual dividend of $0.77 per share, a yield of 0.87%, with a payout ratio of 43.0%.
  • Return on equity was 24.8% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 55.62 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

iRadimed Corporation (IRMD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IRMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com